Blueprint Medicines (BPMC) Tops Q3 EPS by 17c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.62), $0.17 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Investcorp Credit Management BDC, Inc. (ICMB) Misses Q2 EPS by 12c
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c